Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 203 of the 207 references it cites were found in a registry or an index; 164 of the 253 sources its claims cite were checked for support.

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

Open access

Abstract

Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events. Consequently, novel pharmaceutical drugs have been developed to control and modify the composition of blood lipids to ultimately prevent fatal cardiovascular events in patients with dyslipidaemia. This article reviews established and emerging lipid-lowering drugs regarding their mechanism of action, development stage, ongoing clinical trials, side effects, effect on blood lipids and reduction in cardiovascular morbidity and mortality. We conducted a keyword search to identify studies on established and emerging lipid modifying drugs. Results were summarized in a narrative overview. Established pharmaceutical treatment options include the Niemann-Pick-C1 like-1 protein (NPC1L1) inhibitor ezetimibe, the protein convertase subtilisin-kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab, fibrates as peroxisome proliferator receptor alpha (PPAR-α) activators, and the omega-3 fatty acid icosapent ethyl. Statins are recommended as the first-line therapy for primary and secondary cardiovascular prevention in patients with hypercholesterinaemia and hypertriglyceridemia. For secondary prevention in hypercholesterinaemia, second-line options such as statin add-on or statin-intolerant treatments are ezetimibe, alirocumab and evolocumab. For secondary prevention in hypertriglyceridemia, second-line options such as statin add-on or statin-intolerant treatments are icosapent ethyl and fenofibrate. Robust data for these add-on therapeutics in primary cardiovascular prevention remains scarce. Recent biotechnological advances have led to the development of innovative small molecules (bempedoic acid, lomitapide, pemafibrate, docosapentaenoic and eicosapentaenoic acid), antibodies (evinacumab), antisense oligonucleotides (mipomersen, volanesorsen, pelcarsen, olezarsen), small interfering RNA (inclisiran, olpasiran), and gene therapies for patients with dyslipidemia. These molecules specifically target new cellular pathways, such as the adenosine triphosphate-citrate lyase (bempedoic acid), PCSK9 (inclisiran), angiopoietin-like 3 (ANGPTL3: evinacumab), microsomal triglyceride transfer protein (MTP: lomitapide), apolipoprotein B-100 (ApoB-100: mipomersen), apolipoprotein C-III (ApoC-III: volanesorsen, olezarsen), and lipoprotein (a) (Lp(a): pelcarsen, olpasiran). The authors are hopeful that the development of new treatment modalities alongside new therapeutic targets will further reduce patients' risk of adverse cardiovascular events. Apart from statins, data on new drugs' use in primary cardiovascular prevention remain scarce. For their swift adoption into clinical routine, these treatments must demonstrate safety and efficacy as well as cost-effectiveness in randomized cardiovascular outcome trials.

Overview

CoChat Summary

TL;DR

This narrative review summarizes established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention, with emphasis on mechanisms, trial results, side effects, and guideline positioning. It concludes that statins remain first-line, while newer agents such as bempedoic acid, inclisiran, pelacarsen, and olpasiran may expand treatment options but still need stronger outcomes and cost-effectiveness data.

Key findings

  • Statins are first-line therapy; a 1 mmol/L LDL-C reduction was associated with a 22% lower risk of MACE, and low-/moderate-intensity statins reduced MACE by 22% (95% CI 19–24), with an additional 15% reduction from intensification.
  • Ezetimibe added to simvastatin in 18,144 post-ACS patients reduced MACE by 6% (95% CI 1–11, p = 0.016); in EWTOPIA 75, ezetimibe monotherapy in 3,796 patients aged ≥75 years reduced MACE by 34% (HR 0.66, 95% CI 0.50–0.86, p = 0.002).
  • PCSK9 inhibitors reduced LDL-C by about 60% and lowered MACE by 15% in FOURIER and ODYSSEY; the trials randomized 27,564 and 18,924 patients, respectively.
  • Bempedoic acid in CLEAR Outcomes randomized 13,970 statin-intolerant/high-risk patients and reduced MACE by 13% (HR 0.87, 95% CI 0.79–0.96, p = 0.004) with a 21.1% greater LDL-C reduction versus placebo; pemafibrate lowered triglycerides by 26% in PROMINENT but did not significantly reduce MACE (HR 1.03, 95% CI 0.91–1.15).

Methods

  • Narrative review of established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention, covering mechanism of action, developmental stage, safety, lipid effects, and cardiovascular outcomes.
  • The authors state they conducted a keyword search to identify studies on established and emerging lipid-modifying drugs and summarized results in a narrative overview.
  • Evidence synthesized includes guidelines, randomized controlled trials, meta-analyses, and ongoing cardiovascular outcomes trials.

Limitations

  • The paper states that robust data for add-on therapies in primary cardiovascular prevention remain scarce.
  • It also states that many new drugs still need to demonstrate safety, efficacy, and cost-effectiveness in randomized cardiovascular outcome trials before routine adoption.
  • Evident from the text: this is a narrative review, so conclusions depend on heterogeneous studies and many outcomes are reported across different populations and follow-up periods rather than from one uniform analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40256-023-00594-5

Cites

203 of 203 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Established lipid-lowering therapies for cardiovascular prevention. LDL-C, TG and MACE reductions for ezetimibe, evolocumab, alirocumab, fibrates and icosapent ethyl are presented for combination therapy with statins. Data sources as referenced in the accompanying text passages. aThe presented MACE reduction for high-intensity statins refers to the incremental benefit relative to low-/medium-intensity statins. HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A, IV intravenous, LDL-C low-density lipoprotein cholesterol, MACE major adverse cardiovascular events, MoA mechanism of action, NPC1L1 Niemann-Pick C1-like 1 protein, PCSK9 proprotein convertase subtilisin-kexin type 9, PO perioral, PPAR-α peroxisome proliferator receptor alpha, RoA route of administration, SC subcutaneous, TG triglyceride
Fig. 1 Established lipid-lowering therapies for cardiovascular prevention. LDL-C, TG and MACE reductions for ezetimibe, evolocumab, alirocumab, fibrates and icosapent ethyl are presented for combination therapy with statins. Data sources as referenced in the accompanying text passages. aThe presented MACE reduction for high-intensity statins refers to the incremental benefit relative to low-/medium-intensity statins. HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A, IV intravenous, LDL-C low-density lipoprotein cholesterol, MACE major adverse cardiovascular events, MoA mechanism of action, NPC1L1 Niemann-Pick C1-like 1 protein, PCSK9 proprotein convertase subtilisin-kexin type 9, PO perioral, PPAR-α peroxisome proliferator receptor alpha, RoA route of administration, SC subcutaneous, TG triglycerideCC BY-NC · PubMed Central
Fig. 2 ESC and AHA/ACC guidelines for cholesterol-lowering treatments. We extracted recommendations for statins, ezetimibe and PCSK9 inhibitors in the treatment of patients with elevated plasma cholesterol from ESC 2019 and AHA/ACC/multi-society 2018 guidelines. For AHA/ACC/multi-society guidelines, the COR is categorized as class I (strong), class IIa (moderate), class IIb (weak), class III: no benefit (moderate) and class III: harm (strong). For ESC guidelines, the COR is categorized as class I (recommended) class IIa (should be considered), class IIb (may be considered) and class III (not recommended). For US guidelines, the LOE is categorized as level A (high-quality randomized evidence), level B-R (moderate-quality randomized evidence), level B-NR (moderate-quality non-randomized evidence), level C-LD (limited data) and level C-EO (expert opinion). For EU guidelines, the LOE is categorized as level A (data from multiple RCT or meta-analyses), level B (data from one RCT or large non-randomized trial) and level C (consensus expert opinion and/or small studies, retrospective studies, registries). ACC American College of Cardiology, AHA American Heart Association, ASCVD atherosclerotic cardiovascular disease, COR class (strength) of recommendation, CVD cardiovascular disease, ESC European Society of Cardiology, FH familial hypercholesterolemia, LDL-C low-density lipoprotein cholesterol, LOE level (quality) of evidence, PCSK9 proprotein convertase subtilisin-kexin type 9, RCT randomized controlled trial
Fig. 2 ESC and AHA/ACC guidelines for cholesterol-lowering treatments. We extracted recommendations for statins, ezetimibe and PCSK9 inhibitors in the treatment of patients with elevated plasma cholesterol from ESC 2019 and AHA/ACC/multi-society 2018 guidelines. For AHA/ACC/multi-society guidelines, the COR is categorized as class I (strong), class IIa (moderate), class IIb (weak), class III: no benefit (moderate) and class III: harm (strong). For ESC guidelines, the COR is categorized as class I (recommended) class IIa (should be considered), class IIb (may be considered) and class III (not recommended). For US guidelines, the LOE is categorized as level A (high-quality randomized evidence), level B-R (moderate-quality randomized evidence), level B-NR (moderate-quality non-randomized evidence), level C-LD (limited data) and level C-EO (expert opinion). For EU guidelines, the LOE is categorized as level A (data from multiple RCT or meta-analyses), level B (data from one RCT or large non-randomized trial) and level C (consensus expert opinion and/or small studies, retrospective studies, registries). ACC American College of Cardiology, AHA American Heart Association, ASCVD atherosclerotic cardiovascular disease, COR class (strength) of recommendation, CVD cardiovascular disease, ESC European Society of Cardiology, FH familial hypercholesterolemia, LDL-C low-density lipoprotein cholesterol, LOE level (quality) of evidence, PCSK9 proprotein convertase subtilisin-kexin type 9, RCT randomized controlled trialCC BY-NC · PubMed Central
Fig. 3 ESC and AHA/ACC guidelines for hypertriglyceridemia treatments. We extracted recommendations for statins, icosapent ethyl and fibrates in the treatment of hypertriglyceridemia from ESC 2019 and AHA/ACC/multi-society 2018 guidelines. For AHA/ACC/multi-society guidelines, the COR is categorized as class I (strong), class IIa (moderate), class IIb (weak), class III: no benefit (moderate) and class III: harm (strong). For ESC guidelines, the COR is categorized as class I (recommended) class IIa (should be considered), class IIb (may be considered) and class III (not recommended). For US guidelines, the LOE is categorized as level A (high-quality randomized evidence), level B-R (moderate-quality randomized evidence), level B-NR (moderate-quality non-randomized evidence), level C-LD (limited data) and level C-EO (expert opinion). For EU guidelines, the LOE is categorized as level A (data from multiple RCT or meta-analyses), level B (data from one RCT or large non-randomized trial) and level C (consensus expert opinion and/or small studies, retrospective studies, registries). ACC American College of Cardiology, AHA American Heart Association, ASCVD atherosclerotic cardiovascular disease, COR class (strength) of recommendation, CVD cardiovascular disease, ESC European Society of Cardiology, LDL-C low-density lipoprotein cholesterol, LOE level (quality) of evidence, RCT randomized-controlled trial, TG triglyceride
Fig. 3 ESC and AHA/ACC guidelines for hypertriglyceridemia treatments. We extracted recommendations for statins, icosapent ethyl and fibrates in the treatment of hypertriglyceridemia from ESC 2019 and AHA/ACC/multi-society 2018 guidelines. For AHA/ACC/multi-society guidelines, the COR is categorized as class I (strong), class IIa (moderate), class IIb (weak), class III: no benefit (moderate) and class III: harm (strong). For ESC guidelines, the COR is categorized as class I (recommended) class IIa (should be considered), class IIb (may be considered) and class III (not recommended). For US guidelines, the LOE is categorized as level A (high-quality randomized evidence), level B-R (moderate-quality randomized evidence), level B-NR (moderate-quality non-randomized evidence), level C-LD (limited data) and level C-EO (expert opinion). For EU guidelines, the LOE is categorized as level A (data from multiple RCT or meta-analyses), level B (data from one RCT or large non-randomized trial) and level C (consensus expert opinion and/or small studies, retrospective studies, registries). ACC American College of Cardiology, AHA American Heart Association, ASCVD atherosclerotic cardiovascular disease, COR class (strength) of recommendation, CVD cardiovascular disease, ESC European Society of Cardiology, LDL-C low-density lipoprotein cholesterol, LOE level (quality) of evidence, RCT randomized-controlled trial, TG triglycerideCC BY-NC · PubMed Central
Fig. 4 Emerging pharmaceutical therapies for the treatment of dyslipidemia. Drug types were categorized and illustrated as small molecules (capsule), antibodies (syringe) and gene therapeutics (double-stranded DNA helix). Data sources as referenced in the accompanying text passages. aThe drug class could not be identified for the compound NNC0385-0434 A. ANGPTL3 angiopoietin-like 3, ApoB-100 apolipoprotein B-100, ApoC-III apolipoprotein C-III, ATP adenosine triphosphate, CVOT cardiovascular outcome trial, FCS familial chylomicronemia syndrome, FDA US Food and Drug Administration approval, HeFH heterozygous familial hypercholesterolemia, HoFH homozygous familial hypercholesterolemia, HTG hypertriglyceridemia, IV intravenous, Lp(a) lipoprotein(a), MoA mechanism of action, MTG microsomal triglyceride transfer protein, P0 pre-clinic, P1 phase 1, P2 phase 2, P3 phase 3, PCSK9 proprotein convertase subtilisin-kexin type 9, PPAR-α peroxisome proliferator receptor alpha, PO perioral, RoA route of administration, SC subcutaneous, sHTG severe hypertriglyceridemia, siRNA small interfering ribonucleic acid
Fig. 4 Emerging pharmaceutical therapies for the treatment of dyslipidemia. Drug types were categorized and illustrated as small molecules (capsule), antibodies (syringe) and gene therapeutics (double-stranded DNA helix). Data sources as referenced in the accompanying text passages. aThe drug class could not be identified for the compound NNC0385-0434 A. ANGPTL3 angiopoietin-like 3, ApoB-100 apolipoprotein B-100, ApoC-III apolipoprotein C-III, ATP adenosine triphosphate, CVOT cardiovascular outcome trial, FCS familial chylomicronemia syndrome, FDA US Food and Drug Administration approval, HeFH heterozygous familial hypercholesterolemia, HoFH homozygous familial hypercholesterolemia, HTG hypertriglyceridemia, IV intravenous, Lp(a) lipoprotein(a), MoA mechanism of action, MTG microsomal triglyceride transfer protein, P0 pre-clinic, P1 phase 1, P2 phase 2, P3 phase 3, PCSK9 proprotein convertase subtilisin-kexin type 9, PPAR-α peroxisome proliferator receptor alpha, PO perioral, RoA route of administration, SC subcutaneous, sHTG severe hypertriglyceridemia, siRNA small interfering ribonucleic acidCC BY-NC · PubMed Central

Verification

Claims the paper makes

85 Valid · 16 Not valid · 31 Not checked · 13 Own results and interpretations

80 more claims · 55 with their cited sources checked

Create a free account to see all 145 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 12
  • It may state two separate claims as one. 48
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 207 references

Research works printed but not linked: 2

  1. Ollendorf DA, McQueen RB, Campbell JD, et al. Additive therapies for cardiovascular disease: effectiveness and value. 2019.http://icer-review.org/material/cvd-final-evidence-report/. Accessed 22 Mar 2021.
  2. Amgen. Amgen announces positive topline phase 2 data for investigational olpasiran in adults with elevated lipoprotein(a). 2022. https://www.amgen.com/newsroom/press-releases/2022/05/amgen-announces-positive-topline-phase-2-data-for-investigational-olpasiran-in-adults-with-elevated-lipoproteina. Accessed 21 Sep 2022.

Cited by

See all 109

Metadata

Authors
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T.
Affiliations
  • University Hospital Heidelberg (DE)
  • LMU Klinikum (DE)
  • TUM Klinikum (DE)
  • German Cancer Research Center (DE)
Corresponding author
Michaeli, Daniel Tobias
Venue
American Journal of Cardiovascular Drugs
Published
2023-07-24
Volume
23
Issue
5
Pages
477-495
ISSN
  • 1175-3277 (ISSN-L)
  • 1179-187X
OpenAlex
W4385186774
Cited by
109
References
207
Citations by year
2026: 31 · 2025: 40 · 2024: 35 · 2023: 3
FWCI
29.07
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by-nc)
Funders
Universitätsklinikum Heidelberg
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
lipid-lowering drugs, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cardiovascular disease prevention, statins, ezetimibe, PCSK9 inhibitors, fibrates, icosapent ethyl, fenofibrate, bempedoic acid, lomitapide, evinacumab, mipomersen, volanesorsen, olpasiran, inclisiran, olaparib, PCSK9, ANGPTL3, microsomal triglyceride transfer protein, LDL-C
MeSH terms
Ezetimibe, Proprotein Convertase 9, Angiopoietin-Like Protein 3, Anticholesteremic Agents, Hypolipidemic Agents, Cardiovascular Diseases, Dicarboxylic Acids, Pharmaceutical Preparations, Fatty Acids, Humans, Hypertriglyceridemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. https://app.cochat.ai/papers/10.1007/s40256-023-00594-5
The paper
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023). Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-023-00594-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.